Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTHNASDAQ:OHRPNASDAQ:ONCSNASDAQ:PRANNASDAQ:RGLS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$2.64+6.0%$5.01$2.35▼$44.80$1.80M0.351.12 million shs155,717 shsOHRPOHR Pharmaceutical$0.42$7.37$1.60▼$6.28$1.19M0.84180,228 shs21,218 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsPRANAlterity Therapeutics$2.33+9.4%$1.41$1.09▼$2.91$20.74M1.05130,956 shs173,935 shsRGLSRegulus Therapeutics$2.27+2.3%$2.17$1.08▼$3.79$148.59M1.572.42 million shs97,798 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-7.26%-22.91%-35.58%-73.17%-90.78%OHRPOHR Pharmaceutical0.00%+0.26%-57.90%-30.07%+197.53%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-70.60%PRANAlterity Therapeutics+9.39%+15.92%+36.26%+15.94%-17.81%RGLSRegulus Therapeutics-1.77%-5.13%-21.28%+74.80%+63.24%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.3593 of 5 stars3.52.00.00.02.30.00.6OHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGLSRegulus Therapeutics2.4 of 5 stars4.42.00.00.02.01.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path3.00Buy$40.001,415.15% UpsideOHRPOHR PharmaceuticalN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/ARGLSRegulus Therapeutics2.80Moderate Buy$7.25219.38% UpsideCurrent Analyst RatingsLatest PRAN, RGLS, OHRP, BPTH, and ONCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.003/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AOHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/APRANAlterity Therapeutics$150K138.25N/AN/A$1.40 per share1.66RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)OHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/APRANAlterity Therapeutics-$6.40M-$0.70N/A∞N/AN/AN/AN/AN/ARGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)Latest PRAN, RGLS, OHRP, BPTH, and ONCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/A3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A1.601.60OHRPOHR PharmaceuticalN/A3.733.73ONCSOncoSec MedicalN/A0.890.89PRANAlterity TherapeuticsN/A4.37N/ARGLSRegulus TherapeuticsN/A3.313.31OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%OHRPOHR Pharmaceutical10.70%ONCSOncoSec Medical8.69%PRANAlterity Therapeutics3.63%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path3.05%OHRPOHR Pharmaceutical12.50%ONCSOncoSec Medical1.32%PRANAlterity Therapeutics38.80%RGLSRegulus Therapeutics8.41%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path10680,000658,000OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionablePRANAlterity Therapeutics148.90 millionN/ANot OptionableRGLSRegulus Therapeutics3065.46 million59.96 millionOptionablePRAN, RGLS, OHRP, BPTH, and ONCS HeadlinesSourceHeadlineRegulus Therapeutics (NASDAQ:RGLS) Shares Cross Above 200-Day Moving Average of $1.61americanbankingnews.com - April 24 at 3:44 AMRegulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDseekingalpha.com - April 10 at 1:50 PMBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needsmarkets.businessinsider.com - March 28 at 2:29 PMShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3%marketbeat.com - March 27 at 10:53 AMBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestonesmarkets.businessinsider.com - March 26 at 3:28 AMRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at HC Wainwrightmarketbeat.com - March 25 at 8:21 AMRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancementsfinance.yahoo.com - March 23 at 10:30 AMRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinanznachrichten.de - March 22 at 7:21 AMRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 11:00 PMRegulus: Q4 Earnings Snapshottimesunion.com - March 21 at 9:20 PMRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinance.yahoo.com - March 21 at 4:20 PMBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Datamarkets.businessinsider.com - March 19 at 11:39 PMRGLS Mar 2024 7.500 putfinance.yahoo.com - March 15 at 5:16 AMBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & Morefinance.yahoo.com - March 14 at 2:15 PM$100 million fundraise for antisense firm working in nephrologythepharmaletter.com - March 13 at 7:40 PMRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial Positionmarkets.businessinsider.com - March 13 at 2:40 PMRegulus (RGLS) Up 71% on Topline Data from Kidney Disease Studyzacks.com - March 13 at 1:11 PMRegulus Therapeutics Shares Soar on Funding, Study Datamarketwatch.com - March 12 at 7:11 PMRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 Mlnmarkets.businessinsider.com - March 12 at 2:10 PMWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?msn.com - March 12 at 2:10 PMRegulus cues up $100m placement on ADPKD drug datapharmaphorum.com - March 12 at 9:10 AMConsumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bellmsn.com - March 12 at 9:10 AMRegulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429markets.businessinsider.com - March 12 at 9:10 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Alterity TherapeuticsNASDAQ:PRANAlterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.